Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 6
Submit an article Journal homepage
601
Views
100
CrossRef citations to date
0
Altmetric
Review

The potential of proteasome inhibitors in cancer therapy

Jan Sterz Charité-Universitätsmedizin Berlin, Department of Hematology and Oncology, Charité-Platz 1, 10117 Berlin, Germany +49 30 450 613105; +49 30 450 527907; [email protected]
,
Ivana von Metzler Charité-Universitätsmedizin Berlin, Department of Hematology and Oncology, Charité-Platz 1, 10117 Berlin, Germany +49 30 450 613105; +49 30 450 527907; [email protected]
,
Jens-Claus Hahne Charité-Universitätsmedizin Berlin, Department of Hematology and Oncology, Charité-Platz 1, 10117 Berlin, Germany +49 30 450 613105; +49 30 450 527907; [email protected]
,
Britta Lamottke Charité-Universitätsmedizin Berlin, Department of Hematology and Oncology, Charité-Platz 1, 10117 Berlin, Germany +49 30 450 613105; +49 30 450 527907; [email protected]
,
Jessica Rademacher Charité-Universitätsmedizin Berlin, Department of Hematology and Oncology, Charité-Platz 1, 10117 Berlin, Germany +49 30 450 613105; +49 30 450 527907; [email protected]
,
Ulrike Heider Charité-Universitätsmedizin Berlin, Department of Hematology and Oncology, Charité-Platz 1, 10117 Berlin, Germany +49 30 450 613105; +49 30 450 527907; [email protected]
,
Evangelos Terpos 251 General Airforce Hospital, Department of Hematology & Medical Research, Athens, Greece; Hammersmith Hospital, Department of Hematology, Faculty of Medicine Imperial College London, London, UK
&
Orhan Sezer Charité-Universitätsmedizin Berlin, Department of Hematology and Oncology, Charité-Platz 1, 10117 Berlin, Germany +49 30 450 613105; +49 30 450 527907; [email protected]
 show all
Pages 879-895 | Published online: 21 May 2008

Bibliography

  • Hershko A, Ciechanover A. The ubiquitin system. Ann Rev Biochem 1998;67:425-79
  • Bochtler M, Ditzel L, Groll M, et al. The proteasome. Ann Rev Biophys Biomol Struct 1999;28:295-317
  • Fuchs SY. The role of ubiquitin-proteasome pathway in oncogenic signaling. Cancer Biol Ther 2002;1:337-41
  • Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003;8:508-13
  • Newton K, Vucic D. Ubiquitin ligases in cancer: ushers for degradation. Cancer Invest 2007;25:502-13
  • Seeger M, Ferrell K, Dubiel W. The 26S proteasome: a dynamic structure. Mol Biol Rep 1997;24:83-8
  • Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Ann Rev Biochem 1996;65:801-47
  • Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 2000;18:109-21
  • Glickman MH, Rubin DM, Fu H, et al. Functional analysis of the proteasome regulatory particle. Mol Biol Rep 1999;26:21-8
  • Cayrol C, Ducommun B. Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene 1998;17:2437-44
  • Blagosklonny MV, Wu GS, Omura S, El-Deiry WS. Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Commun 1996;227:564-9
  • Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Ann Rev Pharmacol Toxicol 1999;39:295-312
  • Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 1996;56:2649-54
  • Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996;56:4620-4
  • Marshansky V, Wang X, Bertrand R, et al. Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J Immunol 2001;166:3130-42
  • Stankovski I, Gonen H, Orian A, et al. Degradation of the proto-oncogene product c-Fos by the ubiquitin proteolytic system in vivo and in vitro: identification and characterization of the conjugating enzymes. Mol Cell Biol 1995;15:7106-16
  • Kho CJ, Huggins GS, Endege WO, et al. Degradation of E2A proteins through a ubiquitin-conjugating enzyme, UbcE2A. J Biol Chem 1997;272:3845-51
  • Campanero MR, Flemington EK. Regulation of E2F through ubiquitin-proteasome-dependent degradation: stabilization by the pRB tumor suppressor protein. Proc Natl Acad Sci USA 1997;94:2221-6
  • Traenckner EB, Wilk S, Baeuerle PA. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J 1994;13:5433-41
  • Chauhan D, Hideshima T, Anderson KC. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer 2006;95:961-5
  • Orlowski RZ, Stewart K, Vallone M, et al. Safety and antitumor efficacy of the proteasome inhibitor carfilzomib (PR-171) dosed for five consecutive days in hematological malignancies: phase 1 results [abstract 409]. Blood 2007;110(Suppl 1)
  • Zavrski I, Jakob C, Schmid P, et al. Proteasome: an emerging target for cancer therapy. Anticancer Drugs 2005;16:475-81
  • Chang YC, Lee YS, Tejima T, et al. Mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ 1998;9:79-84
  • Yang Y, Yu X. Regulation of apoptosis: the ubiquitous way. FASEB J 2003;17:790-9
  • Brown K, Park S, Kanno T, et al. Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. Proc Natl Acad Sci USA 1993;90:2532-6
  • Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000;20:2687-95
  • Zong WX, Edelstein LC, Chen C, et al. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNF alpha-induced apoptosis. Genes Dev 1999;13:382-7
  • Takahashi S, Harigae H, Ishii KK, et al. Over-expression of Flt3 induces NF-kappaB pathway and increases the expression of IL-6. Leuk Res 2005;29:893-9
  • Bogner C, Peschel C, Decker T. Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach. Leuk Lymphoma 2006;47:195-205
  • Riedl SJ, Salvesen GS. The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol 2007;8:405-13
  • Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22
  • Naujokat C, Sezer O, Zinke H, et al. Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells. Eur J Haematol 2000;65:221-36
  • Zavrski I, Naujokat C, Niemöller K, et al. Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion. J Cancer Res Clin Oncol 2003;129:383-91
  • Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6
  • Shah SA, Potter MW, McDade TP, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001;82:110-22
  • Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-80
  • Johnson TR, Stone K, Nikrad M, et al. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 2003;22:4953-63
  • von Metzler I, Krebbel H, Hecht M, et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007;21:2025-34
  • Ruiz S, Krupnik Y, Keating M, et al. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol Cancer Ther 2006;5:1836-43
  • Anderson KC. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp Hematol 2007;35:155-62
  • Rathmell JC, Thompson CB. Pathways of apoptosis in lymphocyte development, homeostasis, and disease. Cell 2002;109:97-107
  • Wills S, Day CL, Hinds MG, Huang DC. The Bcl-2-regulated apoptotic pathway. J Cell Sci 2003;116:4053-6
  • Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005;8:407-19
  • Miller CP, Ban K, Dujka M, et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007;110:267-77
  • Ahn KS, Sethi G, Chao TH, et al. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappa B regulated gene products. Blood 2007;110:2286-95
  • Chauhan D, Singh A, Brahmandam M, et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008;111:1654-64
  • McCloskey SM, McMullin MF, Walker B, Irvine AE. The therapeutic potential of the proteasome in leukaemia. Hematol Oncol 2008
  • Stapnes C, Døskeland AP, Hatfield K, et al. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol 2007;136:814-28
  • Alsina M, Trudel S, Vallone M, et al. Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematological malignancies [abstract 411]. Blood 2007;110(Suppl 1)
  • Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004;22:2108-21
  • Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS-341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-11
  • Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematological malignancies. J Clin Oncol 2002;20:4420-7
  • Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23
  • Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-72
  • Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17
  • Richardson PG, Barlogie B, Berenson J, et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 2006;106:1316-9
  • Richardson PG, Sonneveld P, Schuster MW, et al.; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98
  • Kane RC, Farrell AT, Sridhara R, Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 2006;12:2955-60
  • Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557-60
  • Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21:151-7
  • Chang H, Trieu Y, Qi X, et al. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res 2007;31:779-82
  • Jagannath S, Richardson PG, Barlogie B, et al. SUMMIT/CREST Investigators. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006;91:929-34
  • Berenson JR, Yang HH, Sadler K, et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006;24:937-44
  • Kropff M, Bisping G, Schuck E, et al. Deutsche Studiengruppe Multiples Myelom. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007;138:330-7
  • Davies FE, Wu P, Jenner M, et al. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to Velcade™ alone and Velcade™ plus dexamethasone. Haematologica 2007;92:1149-50
  • Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892-901
  • Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776-83
  • Harousseau JL, Mathiot C, Attal M, et al. Velcade/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantion (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 trial [abstract 450]. Blood 2007;110(Suppl 1)
  • Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005;129:755-62
  • Oakervee H, Popat R, Cavenagh JD. Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment. Leuk Lymphoma 2007;48:1910-21
  • Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicentre phase 1/2 study. Blood 2006;108:2165-72
  • Mateos MV, Hernández JM, Hernández MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 2008;93:560-5
  • San Miguel J, Schlag R, Khuageva N, et al. MMY-3002: a phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma [abstract 76]. Blood 2007;110(Suppl 1)
  • Palumbo A, Bringhen S, Caravita T, et al. Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-31
  • Facon T, Mary JY, Hulin C, et al. Intergroupe Francophone du Myelome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209-18
  • Palumbo A, Ambrosini MT, Benevolo G, et al.; Italian Multiple Myeloma Network; Gruppo Italiano Malattie Ematologicche dell'Adulto. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007;109:2767-72
  • Masdehors P, Omura S, Merle-Beral H, et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol 1999;105:752-7
  • Orlowski RZ, Eswara JR, Lafond-Walker A, et al. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 1998;58:4342-8
  • Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 2002;62:1083-6
  • Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667-75
  • O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-84
  • Chen CI, Kouroukis CT, White D, et al. National Cancer Institute of Canada Clinical Trials Group. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1570-5
  • Fisher RI, Bernstein SH, Kahl BS, et al. Multicentre phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867-74
  • Belch A, Kouroukis CT, Crump M, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007;18:116-21
  • Kane RC, Dagher R, Farrell A, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007;13:5291-4
  • Heider U, von Metzler I, Kaiser M, et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 2008;80:133-42
  • Barr P, Fisher R, Friedberg J. The role of bortezomib in the treatment of lymphoma. Cancer Invest 2007;25:766-75
  • Cortes J, Thomas D, Koller C, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004;10:3371-6
  • Faderl S, Rai K, Gribben J, et al. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer 2006;107:916-24
  • Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005;105:3058-65
  • Zheng B, Georgakis GV, Li Y, et al. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappa B mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 2004;10:3207-15
  • Blum KA, Johnson JL, Niedzwiecki D, et al. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma 2007;48:1313-9
  • Trelle S, Sezer O, Naumann R, et al. Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018). Haematologica 2007;92:568-9
  • Zhao X, Qiu W, Kung J, et al. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies. Leuk Res 2008;32:275-85
  • Voortman J, Smit EF, Honeywell R, et al. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clin Cancer Res 2007;13:3642-51
  • Yang CH, Gonzalez-Angulo AM, Reuben JM, et al. Bortezomib (Velcade™) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 2006;17:813-7
  • Markovic SN, Geyer SM, Dawkins F, et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 2005;103:2584-9
  • Shah MH, Young D, Kindler HL, et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2004;10:6111-8
  • Alberts SR, Foster NR, Morton RF, et al. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomised Phase II study. Ann Oncol 2005;16:1654-61
  • Fanucchi MP, Fossella FV, Belt R, et al. Randomised phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5025-33
  • Lara PN Jr, Chansky K, Davies AM, et al. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group Phase II trial (S0327). J Thorac Oncol 2006;1:996-1001
  • Aghajanian C, Dizon DS, Sabbatini P, et al. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 2005;23:5943-9
  • Berenson JR, Jagannath S, Barlogie B, et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005;104:2141-8
  • San Miguel J, Bladé J, Boccadoro M, et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 2006;11:51-61
  • Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113-20
  • Richardson PG, Mitsiades C, Schlossman R, et al. New drugs for myeloma. Oncologist 2007;12:664-89
  • Lonial S, Waller EK, Richardson PG, et al. SUMMIT/CREST Investigators. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005;106:3777-84
  • Sezer O, Vesole DH, Singhal S, et al. Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma 2006;7:233-5
  • Terpos E, Politou M, Rahemtulla A, et al. Tumor lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. J Cancer Res Clin Oncol 2004;130:623-5
  • San-Miguel JF, Richardson PG, Sonneveld P, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008
  • Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicentre retrospective study. Blood 2007;109:2604-6
  • Ludwig H, Drach J, Graf H, et al. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 2007;92:1411-4
  • Hecht M, von Metzler I, Sack K, et al. Myeloma cell-osteoclast interaction stimulates expression of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA) through activation of p38 MAPK and STAT3. Exp Cell Res 2008;314:1082-93
  • Hecht M, Heider U, Kaiser M, et al. Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK. Br J Haematol 2007;138:446-58
  • Zangari M, Esseltine D, Lee CK, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005;131:71-3
  • Heider U, Kaiser M, Müller C, et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 2006;77:233-8
  • Giuliani N, Morandi F, Tagliaferri S, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007;110:334-8
  • Terpos E, Sezer O, Croucher P, Dimopoulos MA. Myeloma bone disease and proteasome inhibition therapies. Blood 2007;110:1098-104
  • Terpos E, Dimopoulos MA, Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007;21:1875-84
  • Jakob C, Egerer K, Liebisch P, et al. Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood 2007;109:2100-5
  • Zavrski I, Kleeberg L, Kaiser M, et al. Proteasome as an emerging therapeutic target in cancer. Curr Pharm Des 2007;13:471-85

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.